Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Abstract

SummaryBackgroundSeizures and their consequences contribute to the burden of epilepsy because they can cause health loss (premature mortality and residual disability). Data on the burden of epilepsy are needed for health-care planning and resource allocation. The aim of this study was to quantify health loss due to epilepsy by age, sex, year, and location using data from the Global Burden of Diseases, Injuries, and Risk Factors Study.MethodsWe assessed the burden of epilepsy in 195 countries and territories from 1990 to 2016. Burden was measured as deaths, prevalence, and disability-adjusted life-years (DALYs; a summary measure of health loss defined by the sum of years of life lost [YLLs] for premature mortality and years lived with disability), by age, sex, year, location, and Socio-demographic Index (SDI; a compound measure of income per capita, education, and fertility). Vital registrations and verbal autopsies provided information about deaths, and data on the prevalence and severity of epilepsy largely came from population representative surveys. All estimates were calculated with 95% uncertainty intervals (UIs).FindingsIn 2016, there were 45·9 million (95% UI 39·9–54·6) patients with all-active epilepsy (both idiopathic and secondary epilepsy globally; age-standardised prevalence 621·5 per 100 000 population; 540·1–737·0). Of these patients, 24·0 million (20·4–27·7) had active idiopathic epilepsy (prevalence 326·7 per 100 000 population; 278·4–378·1). Prevalence of active epilepsy increased with age, with peaks at 5–9 years (374·8 [280·1–490·0]) and at older than 80 years of age (545·1 [444·2–652·0]). Age-standardised prevalence of active idiopathic epilepsy was 329·3 per 100 000 population (280·3–381·2) in men and 318·9 per 100 000 population (271·1–369·4) in women, and was similar among SDI quintiles. Global age-standardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 population (1·64–1·87; 1·40 per 100 000 population [1·23–1·54] for women and 2·09 per 100 000 population [1·96–2·25] for men). Age-standardised DALYs were 182·6 per 100 000 population (149·0–223·5; 163·6 per 100 000 population [130·6–204·3] for women and 201·2 per 100 000 population [166·9–241·4] for men). The higher DALY rates in men were due to higher YLL rates compared with women. Between 1990 and 2016, there was a non-significant 6·0% (−4·0 to 16·7) change in the age-standardised prevalence of idiopathic epilepsy, but a significant decrease in age-standardised mortality rates (24·5% [10·8 to 31·8]) and age-standardised DALY rates (19·4% [9·0 to 27·6]). A third of the difference in age-standardised DALY rates between low and high SDI quintile countries was due to the greater severity of epilepsy in low-income settings, and two-thirds were due to a higher YLL rate in low SDI countries.InterpretationDespite the decrease in the disease burden from 1990 to 2016, epilepsy is still an important cause of disability and mortality. Standardised collection of data on epilepsy in population representative surveys will strengthen the...

Long‐term chemogenetic suppression of spontaneous seizures in a mouse model for temporal lobe epilepsy

“…1 Therefore, research toward new means to suppress seizures is very important. More than one-third of patients continue to have seizures despite best available treatment with antiepileptic drugs (AEDs) and many patients have unacceptable drug-related side effects.…”

“…More than one-third of patients continue to have seizures despite best available treatment with antiepileptic drugs (AEDs) and many patients have unacceptable drug-related side effects. 1 Therefore, research toward new means to suppress seizures is very important.…”

Same same but different: A Web‐based deep learning application revealed classifying features for the histopathologic distinction of cortical malformations

“…We hope to help disseminate Web-based digital pathology tools into regions of the world where genetic testing or advanced neuropathology expertise is not a common or even available standard. 49,50 In conclusion, our study demonstrated the successful use of deep learning in the diagnosis of histomorphologically difficult-to-classify MCD entities. Morphological features learned by the system and relevant for the classification of FCD IIb and cortical tuber were then integrated into a fourtiered classification score successfully validated through a Web-based application, thereby boosting the yield of diagnostic accuracy in a nonexpert group to expert level performance.…”

“…We can imagine facilitating elaborated classification and visualization methods as teaching tools for medical students and pathology trainees. We hope to help disseminate Web‐based digital pathology tools into regions of the world where genetic testing or advanced neuropathology expertise is not a common or even available standard …”

Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy

“…Epilepsy is a chronic neurological disease of brain dysfunction that has received widespread attention in society [1,2]. Recent studies have shown that a total of 45.9 million people suffer from epilepsy in the world, which is one of the important causes of disability and death in the population [3].…”